The $8M Problem No One Owns in Clinical Trials — Until Now
Enrollment delays. Fragmented operations. Hidden costs. See how clinical trial leaders are solving this.
Get Instant Access
Why 80% of Clinical Trials Miss Enrollment Targets
And why your current approach can't fix it
Right now, somewhere in your organization:
- A protocol changed. Your recruitment vendor doesn't know.
- Leads came in. Your sites can't screen them efficiently.
- Sites enrolled patients. You have zero visibility.
- Data arrived. Quality issues discovered too late.
- Amendments required. Timelines extended. Costs exploded.
This isn't a recruitment problem. This is an operational problem. And it's costing the industry $8 million per trial.
Fragmentation
Disconnected systems and vendors
Silos
Teams operating in isolation
Ownership Gaps
No single point of accountability
What the Research Actually Shows
Data from the Tufts Center for the Study of Drug Development
$50,000
per day in unrealized drug sales from delays
6-8 months
typical startup delays
80%
of trials fail to meet enrollment targets
These numbers aren't theoretical. They're based on analysis of 645 drugs and 409 clinical trial protocols. The research is clear: enrollment delays don't happen by accident. They happen because of systemic failures.
The webinar breaks down exactly what the Tufts CSDD research means for YOUR trials — and how to prevent it.
Operational Orphaning: The Hidden Killer of Clinical Trials
When no one owns the end-to-end process, everyone pays the price
There's a concept most clinical trial leaders don't have a name for. We call it Operational Orphaning.
It's when no one owns the entire workflow from protocol to enrollment to data lock. The sponsor owns protocol. The recruitment vendor owns leads. The sites own screening. Data Management owns database lock.
Each team owns their piece. But nobody owns the whole picture.
And when nobody owns it, everything breaks.
The webinar explores:
- How Operational Orphaning happens in your organization
- The cascade of failures it creates
- Why traditional solutions can't fix it
- What operational maturity actually looks like
Register for the webinar to see if your trials are suffering from Operational Orphaning.
Fragmented (Current State)
Sponsor
Vendor
Sites
Data
Each owns a piece. No one owns the whole.
Integrated (With TheraNovex)
Single Operational Owner
Sponsor
Vendor
Sites
Data
Connected. Visible. Owned.
What Changes When Operations Finally Have a Single Owner
The operational nervous system that connects everything
Protocol changes →
Instantly visible to all stakeholders
Recruitment generates leads →
Sites screen in real-time
Sites enroll patients →
Sponsors see it immediately
Data comes in →
Quality issues caught early
Amendments prevented →
Timeline stays on track
Full visibility →
Costs stay controlled
The result: Studies stay on schedule. Enrollment accelerates. Costs stay controlled.
But how do you actually implement this? That's what the webinar reveals.
The webinar shows you the framework for operational maturity and the platform in action.
Whether You're a Site Leader or a Sponsor, This Applies to You
For Site Leaders
Sites Are Drowning in Fragmentation
The Pain:
- •20+ hours/week on feasibility assessments for studies you'll never win
- •Managing recruitment across 5+ different systems
- •Drowning in compliance paperwork
- •Losing staff to burnout
The Relief:
- Reclaim 10+ hours/week
- Stop chasing studies. Start being discovered.
- One integrated platform instead of 5+ tools
- Predictable revenue and reduced burnout
For Sponsors
Sponsors Are Managing Chaos
The Pain:
- •6+ months on site selection and activation
- •Activating sites that never enroll (wasted contracts)
- •Managing multiple vendors with zero visibility
- •Protocol amendments from site failures
The Relief:
- Compress activation from 6+ months to 4-6 weeks
- Know which sites will actually perform
- One dashboard for all site management
- De-risk your entire development pipeline
"The best clinical research happens when everyone moves in the same direction."
What You'll Learn in Under 20 Minutes
See exactly where the $8 million cost comes from — and how to eliminate it
The $8M Cost Breakdown
Tufts CSDD research and what it means for your trials
How Operational Orphaning Happens
The cascade of failures in your organization
The Framework for Operational Maturity
What changes when operations are owned
You'll walk away with:
- A clear understanding of where your $8M costs are coming from
- A framework for operational maturity you can implement immediately
- Real examples of how sites and sponsors are accelerating enrollment
- Specific next steps for your organization
Register for the Webinar
Limited spots available. Secure your seat now.
Join clinical trial leaders who are solving the $8M problem.
You'll get:
- Recording link (if you can't attend live)
- Exclusive resources and case studies
- Direct Q&A with TheraNovex experts
Why Clinical Trial Leaders Trust This Research
"The Tufts CSDD research changed how we think about enrollment delays. It's not about working harder—it's about working differently."
— Clinical Operations Leader, Top 20 Pharma
645
Drugs Analyzed
409
Protocols Studied
Research Source
Based on Tufts Center for the Study of Drug Development analysis of 645 drugs and 409 clinical trial protocols (2023)
Industry Recognition
Cited in Applied Clinical Trials, June 2024
Expert Author
Research by Ken Getz, MBA, Tufts CSDD
Proven Scale
Used by 500+ clinical studies
This isn't opinion. This is research. The Tufts Center for the Study of Drug Development has been analyzing clinical trial economics for 40+ years. Their data is the industry standard.
Ready to Solve the $8M Problem?
Start with the webinar. Move to the solution.
The webinar is free. The only cost is the time you spend learning how to eliminate $8M in trial delays.